Einar Sigurdsson

Summary

Affiliation: New York University
Country: USA

Publications

  1. pmc Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice
    E M Sigurdsson
    Department of Neurology, New York University School of Medicine, 550 First Ave, New York, NY 10016, USA
    Am J Pathol 159:439-47. 2001
  2. pmc A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice
    Einar M Sigurdsson
    Department of Psychiatry, New York University School of Medicine, New York, NY 10016, USA
    Neurobiol Aging 29:836-47. 2008
  3. ncbi request reprint Immunotherapy for conformational diseases
    Einar M Sigurdsson
    New York University, School of Medicine, Department of Psychiatry, Millhauser Laboratories, HN418, 560 First Avenue, New York, NY 10016, USA
    Curr Pharm Des 12:2569-85. 2006
  4. pmc Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies
    Einar M Sigurdsson
    Department of Physiology, New York University School of Medicine, New York, NY 10016, USA
    J Alzheimers Dis 15:157-68. 2008
  5. ncbi request reprint An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives
    Einar M Sigurdsson
    Department of Psychiatry, New York University School of Medicine, New York, New York 10016, USA
    J Neurosci 24:6277-82. 2004
  6. ncbi request reprint Copper chelation delays the onset of prion disease
    Einar M Sigurdsson
    Department of Psychiatry, New York University School of Medicine, Millhouser Labs, Room HN418, 560 First Avenue, New York, NY 10016, USA
    J Biol Chem 278:46199-202. 2003
  7. pmc Tau-focused immunotherapy for Alzheimer's disease and related tauopathies
    Einar M Sigurdsson
    New York University School of Medicine, Department of Physiology and Neuroscience, Medical Science Building MSB459, Millhauser Labs Room HN418, 550 First Avenue, New York, NY 10016, USA
    Curr Alzheimer Res 6:446-50. 2009
  8. ncbi request reprint A safer vaccine for Alzheimer's disease?
    Einar M Sigurdsson
    Department of Psychiatry, School of Medicine, New York University, 550 First Avenue, New York 10016, USA
    Neurobiol Aging 23:1001-8. 2002
  9. ncbi request reprint Infectivity of amyloid diseases
    Einar M Sigurdsson
    Department of Psychiatry, New York University, School of Medicine, 560 First Avenue, New York, NY 10016, USA
    Trends Mol Med 8:411-3. 2002
  10. ncbi request reprint Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging
    Joseph F Poduslo
    Molecular Neurobiology Laboratory, Department of Neurology, Mayo Clinic Rochester, Minnesota 55905, USA
    Neurobiol Dis 11:315-29. 2002

Collaborators

Detail Information

Publications27

  1. pmc Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice
    E M Sigurdsson
    Department of Neurology, New York University School of Medicine, 550 First Ave, New York, NY 10016, USA
    Am J Pathol 159:439-47. 2001
    ..These promising findings suggest that immunization with nonamyloidogenic Abeta derivatives represents a potentially safer therapeutic approach to reduce amyloid burden in Alzheimer's disease, instead of using toxic Abeta fibrils...
  2. pmc A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice
    Einar M Sigurdsson
    Department of Psychiatry, New York University School of Medicine, New York, NY 10016, USA
    Neurobiol Aging 29:836-47. 2008
    ..3) Smaller, earlier plaques require contrast ligand for MRI visualization. Our ligand when combined with VBA may be useful for following therapeutic approaches targeting amyloid in transgenic mouse models...
  3. ncbi request reprint Immunotherapy for conformational diseases
    Einar M Sigurdsson
    New York University, School of Medicine, Department of Psychiatry, Millhauser Laboratories, HN418, 560 First Avenue, New York, NY 10016, USA
    Curr Pharm Des 12:2569-85. 2006
    ....
  4. pmc Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies
    Einar M Sigurdsson
    Department of Physiology, New York University School of Medicine, New York, NY 10016, USA
    J Alzheimers Dis 15:157-68. 2008
    ..These antibodies enter the brain and bind to pathological tau within neurons. We are currently clarifying further the mechanism of action of this promising therapeutic approach and determining its epitope specificity...
  5. ncbi request reprint An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives
    Einar M Sigurdsson
    Department of Psychiatry, New York University School of Medicine, New York, New York 10016, USA
    J Neurosci 24:6277-82. 2004
    ..Our results indicate that these nontoxic Abeta derivatives produce an attenuated antibody response, which is less likely to be associated with negative side effects while having cognitive benefits...
  6. ncbi request reprint Copper chelation delays the onset of prion disease
    Einar M Sigurdsson
    Department of Psychiatry, New York University School of Medicine, Millhouser Labs, Room HN418, 560 First Avenue, New York, NY 10016, USA
    J Biol Chem 278:46199-202. 2003
    ..Overall, these findings indicate that copper levels can influence the conformational state of PrP, thereby enhancing its infectivity, and this effect can be attenuated by chelator-based therapy...
  7. pmc Tau-focused immunotherapy for Alzheimer's disease and related tauopathies
    Einar M Sigurdsson
    New York University School of Medicine, Department of Physiology and Neuroscience, Medical Science Building MSB459, Millhauser Labs Room HN418, 550 First Avenue, New York, NY 10016, USA
    Curr Alzheimer Res 6:446-50. 2009
    ..We are currently clarifying the mechanism of these promising findings, determining its epitope specificity as well as assessing the feasibility of this approach for clinical trials...
  8. ncbi request reprint A safer vaccine for Alzheimer's disease?
    Einar M Sigurdsson
    Department of Psychiatry, School of Medicine, New York University, 550 First Avenue, New York 10016, USA
    Neurobiol Aging 23:1001-8. 2002
    ..Future Abeta derived vaccines should include T(h) epitopes, carriers and/or lipid moieties to enhance antibody production in the elderly, the population predominantly affected by AD...
  9. ncbi request reprint Infectivity of amyloid diseases
    Einar M Sigurdsson
    Department of Psychiatry, New York University, School of Medicine, 560 First Avenue, New York, NY 10016, USA
    Trends Mol Med 8:411-3. 2002
    ..Thus, amyloid-related therapeutic approaches should not be based on administration of amyloidogenic peptides in conjunction with an inflammatory stimulus, such as in a recently halted clinical trial for Alzheimer's disease...
  10. ncbi request reprint Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging
    Joseph F Poduslo
    Molecular Neurobiology Laboratory, Department of Neurology, Mayo Clinic Rochester, Minnesota 55905, USA
    Neurobiol Dis 11:315-29. 2002
    ..This could enable early diagnosis and also provide a direct measure of the efficacy of anti-amyloid therapies currently being developed...
  11. pmc Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages
    Ayodeji A Asuni
    Department of Psychiatry, New York University School of Medicine, Millhauser Laboratories, 560 First Avenue, New York, NY 10016, USA
    Eur J Neurosci 24:2530-42. 2006
    ..These findings indicate that our approach age-dependently improves cognition and reduces Abeta burden when used with an adjuvant suitable for humans, without increasing vascular Abeta deposits or microhemorrhages...
  12. ncbi request reprint Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging
    Youssef Zaim Wadghiri
    Skirball Institute of Biomolecular Medicine, New York University School of Medicine, New York, New York 10016, USA
    Magn Reson Med 50:293-302. 2003
    ..This approach provides an in vivo method to detect Abeta in AD transgenic mice, and suggests that diagnostic MRI methods to detect Abeta in AD patients may ultimately be feasible...
  13. ncbi request reprint Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements
    Ayodeji A Asuni
    Department of Psychiatry, New York University School of Medicine, New York, New York 10016, USA
    J Neurosci 27:9115-29. 2007
    ..Currently, no treatment is available for clearing tau aggregates. Our present findings may lead to a novel therapy targeting one of the major hallmarks of Alzheimer's disease and frontotemporal dementia...
  14. pmc Diminished amyloid-beta burden in Tg2576 mice following a prophylactic oral immunization with a salmonella-based amyloid-beta derivative vaccine
    Allal Boutajangout
    Department of Physiology and Neuroscience, New York University School of Medicine, New York, NY 10016, USA
    J Alzheimers Dis 18:961-72. 2009
    ..These results further support our findings with this immunogen delivered subcutaneously and demonstrate its efficacy when given orally, which may provide added benefits for human use...
  15. pmc A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice
    Marcin Sadowski
    Department of Neurology, New York University School of Medicine, New York, New York, USA
    Am J Pathol 165:937-48. 2004
    ..Our experiments demonstrate that compounds blocking the interaction between Abeta and its pathological chaperones may be beneficial for treatment of beta-amyloid deposition in AD...
  16. ncbi request reprint Therapeutic approaches for prion and Alzheimer's diseases
    Thomas Wisniewski
    Department of Neurology, New York University School of Medicine, NY 10016, USA
    FEBS J 274:3784-98. 2007
    ..Therefore, there is a great need for effective therapies for both Alzheimer's disease and prion diseases...
  17. ncbi request reprint Immunization treatment approaches in Alzheimer's and prion diseases
    Thomas Wisniewski
    Department of Neurology, New York University Medical Center, Millhauser Laboratory, HN419, 550 First Avenue, New York, NY 10016, USA
    Curr Neurol Neurosci Rep 2:400-4. 2002
    ..These immune-based treatment approaches have great potential as rational therapies for this devastating group of disorders, but additional development is needed before they can be safely applied to humans...
  18. pmc Immunization delays the onset of prion disease in mice
    Einar M Sigurdsson
    Department of Psychiatry, New York University School of Medicine, New York, New York 10016, USA
    Am J Pathol 161:13-7. 2002
    ..The increase in the incubation period closely correlated with the anti-prion protein antibody titer. This promising finding suggests that a similar approach may work in humans or other mammalian species at risk for prion disease...
  19. pmc Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging
    Henrieta Scholtzova
    Department of Neurology, New York University School of Medicine, New York, New York 10016, USA
    J Neurosci Res 86:2784-91. 2008
    ..In addition, our study shows, for the first time, the utility of micro MRI in conjunction with gadolinium-labeled A beta labeling agents to monitor the therapeutic response to amyloid-reducing agents...
  20. pmc Murine models of Alzheimer's disease and their use in developing immunotherapies
    Thomas Wisniewski
    Department of Neurology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    Biochim Biophys Acta 1802:847-59. 2010
    ..Because of these uncertainties, Tg models for AD are continuously being refined with the aim to better understand the disease and to enhance the predictive validity of potential treatments such as immunotherapies...
  21. ncbi request reprint Anti-prion antibodies for prophylaxis following prion exposure in mice
    Einar M Sigurdsson
    Department of Psychiatry, New York University School of Medicine, Millhauser Laboratory, 550 First Avenue, New York, NY 10016, USA
    Neurosci Lett 336:185-7. 2003
    ..Stimulation of the immune system is an important therapeutic target for the prion diseases, as well as for other neurodegenerative illnesses characterized by abnormal protein conformation...
  22. ncbi request reprint New directions towards safer and effective vaccines for Alzheimer's disease
    Fernando Goni
    New York University, Departments of Psychiatry, School of Medicine, New York, NY 10016, USA
    Curr Opin Mol Ther 7:17-23. 2005
    ....
  23. ncbi request reprint Magnetic resonance imaging of amyloid plaques in transgenic mice
    Youssef Zaim Wadghiri
    Skirball Institute of Biomolecular Medicine and Department of Radiology, New York University School of Medicine, NY, USA
    Methods Mol Biol 299:365-79. 2005
    ....
  24. ncbi request reprint Histological staining of amyloid-beta in mouse brains
    Einar M Sigurdsson
    Department of Psychiatry, New York University School of Medicine, NY, USA
    Methods Mol Biol 299:299-308. 2005
    ..These sections can as well be used for immunohistological procedures that allow detection of amyloid-beta plaques as well as pre-amyloid deposits...
  25. ncbi request reprint Plaque-associated overexpression of insulin-degrading enzyme in the cerebral cortex of aged transgenic tg2576 mice with Alzheimer pathology
    Maria C Leal
    Fundacion Instituto Leloir, Instituto de Investigaciones Bioquímicas de Buenos Aires, CONICET, Ciudad de Buenos Aires, Argentina
    J Neuropathol Exp Neurol 65:976-87. 2006
    ..We propose that in Tg2576 mice and in contrast to its behavior in Alzheimer brains, active IDE increases with age around plaques as a component of astrocyte activation as a result of Abeta-triggered inflammation...
  26. ncbi request reprint Promising developments in prion immunotherapy
    Einar M Sigurdsson
    Expert Rev Vaccines 4:607-10. 2005
  27. ncbi request reprint Amyloid fibril formation by macrophage migration inhibitory factor
    Hilal A Lashuel
    Integrative Biosciences Institute, Laboratory of Molecular Neurobiology and Neuroproteomics, Swiss Federal Institute of Technology EPFL, CH 1015 Lausanne, Switzerland
    Biochem Biophys Res Commun 338:973-80. 2005
    ....

Research Grants13

  1. Immune Therapy and Imaging in Mouse and Primate Models of Alzheimer's Disease
    Einar M Sigurdsson; Fiscal Year: 2010
    ..The second aim will be performed in transgenic mouse models of AD because of the larger number of animals required and/or because of the earlier developmental stage of those approaches. ..
  2. Clearance and In Vivo Detection of Tau Pathology
    Einar Sigurdsson; Fiscal Year: 2009
    ....
  3. Immune Therapy and Imaging in Mouse and Primate Models of Alzheimer's Disease
    Einar Sigurdsson; Fiscal Year: 2009
    ..The second aim will be performed in transgenic mouse models of AD because of the larger number of animals required and/or because of the earlier developmental stage of those approaches. ..
  4. Immunotherapy for Pancreatic Amylin Aggregates in Diabetes
    Einar Sigurdsson; Fiscal Year: 2007
    ..We and others have had success with similar approaches in other amyloid diseases such as Alzheimer's-, prion-, and Parkinson's disease. These studies could lead to novel treatments for type-2 diabetes. ..
  5. Immune Therapy for AD plaques and Tangles in Tg Mice
    Einar Sigurdsson; Fiscal Year: 2005
    ..Furthermore, because of numerous reports of cellular uptake of antibodies, intracellular tangles may also be affected, leading to reduced neuronal loss and thereby slowing of cognitive deterioration. ..
  6. Clearance and In Vivo Detection of Tau Pathology
    Einar M Sigurdsson; Fiscal Year: 2010
    ....